Development of Seraseq ctDNA Myeloid Mutation Mix: A Reference Material to Monitor Sensitivity and Specificity of NGS-Based Testing in Myeloid Blood Cancers Free Infographic

Request Your Free Infographic Now:

"Development of Seraseq ctDNA Myeloid Mutation Mix: A Reference Material to Monitor Sensitivity and Specificity of NGS-Based Testing in Myeloid Blood Cancers"

Free Infographic: "Development of Seraseq ctDNA Myeloid Mutation Mix: A Reference Material to Monitor Sensitivity and Specificity of NGS-Based Testing in Myeloid Blood Cancers"

Myeloid malignancies are characterized by excessive proliferation, abnormal self-renewal, and differentiation defects of hematopoietic stem cells and myeloid progenitor cells. The detection of these types of malignancies using traditional procedures by obtaining bone marrow samples is invasive and risky. Hence, liquid biopsy-based methods are in high demand to monitor and detect new cases of blood cancer.
View full description >

Get Started

Complete the form below:

Work Email Address

First Name

Last Name

Company Name

Job Title

Job Area

Please Specify
for Other:

Work Phone Number

Company Size

Company Industry

Please Specify
for Other:

Company Street Address

Company Suite/Office

Company Postal/Zip Code

Company City

Company State

Company Country

Summary

Valid email address is required to fulfill your request.

To learn more about how your data is processed, stored, and kept secure please read our Privacy Policy.

	Pharmaceutical/Biopharmaceutical Company	Ag-Bio Company
	Contract Research Organization	Genomic Services Provider
	Diagnostic Developer	Instrument Manufacturer/Vendor
	Core Lab	Academic/University/Nonprofit Research Institute
	Government Agency	CLIA Lab: Hospital
	CLIA Lab: Independent	CLIA Lab: Physician/Group Practice
	Hospital/Medical Center	Private/Group Medical Practice
	Management Consultant/Venture Capital/Law Firm	Public Relations/Advertising Firm

Request Your Free Infographic Now: